Therapy: is the attempted remediation of a health problem, usually following a diagnosis. In the medical field, it is usually synonymous with treatment.
DATE: November 15, 2019TIME: 8:00am PST, 11:00am EST Exosomes are small vesicles, ranging from 30-120 nanometers in diameter, secreted from cells throughout the human body. The...
DATE: November 13, 2019TIME: 12:00pm PT NK cells play a major role in immune surveillance and in the early immune response to cancer and infections. Beneficial anti-tumor respo...
DATE: November 7, 2019 TIME: 9:00am PST, 12:00pm EST In collaboration with Hematherix and Thermo Fisher, Dr. Laurent Mosnier is investigating a new treatment for acute traumatic bl...
DATE: November 5, 2019TIME: 9:00am PT, 12:00pm ET New results have highlighted the advantages of minicircles over plasmids as they avoid unnecessary bacterial backbone sequences...
DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
DATE: October 29, 2019TIME: 8:00am PDTAlthough immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some pati...
The emergence of medicinal hemp represents a new frontier in medicine; one which has tremendous potential for patients struggling with a wide array of illnesses. However, in order to fully ca...
Calprotectin is a member of the S100 family of calcium binding proteins, being a hetero dimmer of S100A8/9 and accounts for 60% of the protein in the cytoplasm of neutrophils. It is released...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
Copy-number alterations and chromosomal translocations are widespread in cancer and frequently causing oncogenic mutations that drive tumorigenesis and therapy resistance. Despite their preva...
The introduction of robot-assisted surgical technology into urological practice, has introduced new horizons for reducing the morbidity and enhancing the efficacy of surgery. Open radical cys...
This presentation will review the utility of multiparametric MRI (mpMRI) and genomic testing in the management of early stage prostate cancer and show when and if such tests should be used al...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Although about one in every seven men in the developed world will be diagnosed with prostate cancer in their lifetime, the mortality rate remains low with a 99% five-year survival rate for lo...
Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading cau...
Novel precision genetic technologies such as CRISPR/Cas9 genome editing technology offer novel avenues to a better understanding the mechanisms of diseases. Using CRISPR/Cas9 we are able to p...
Over the last decade, the policy and regulatory trajectory of genomic and reproductive technologies has been a checkered one. Approaches around the world range from constitutional and crimina...
CRISPR based gene editing has proven to be an incredibly powerful tool for studying functions of individual proteins, understanding the role of multi-gene pathways, and even knocking out prot...
First discovered as a genome-editing tool just seven years ago, CRISPR systems have already changed the face of basic research, allowing researchers to alter the DNA of hundreds of organisms...
DATE: November 15, 2019TIME: 8:00am PST, 11:00am EST Exosomes are small vesicles, ranging from 30-120 nanometers in diameter, secreted from cells throughout the human body. The...
DATE: November 13, 2019TIME: 12:00pm PT NK cells play a major role in immune surveillance and in the early immune response to cancer and infections. Beneficial anti-tumor respo...
DATE: November 7, 2019 TIME: 9:00am PST, 12:00pm EST In collaboration with Hematherix and Thermo Fisher, Dr. Laurent Mosnier is investigating a new treatment for acute traumatic bl...
DATE: November 5, 2019TIME: 9:00am PT, 12:00pm ET New results have highlighted the advantages of minicircles over plasmids as they avoid unnecessary bacterial backbone sequences...
DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
DATE: October 29, 2019TIME: 8:00am PDTAlthough immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some pati...
The emergence of medicinal hemp represents a new frontier in medicine; one which has tremendous potential for patients struggling with a wide array of illnesses. However, in order to fully ca...
Calprotectin is a member of the S100 family of calcium binding proteins, being a hetero dimmer of S100A8/9 and accounts for 60% of the protein in the cytoplasm of neutrophils. It is released...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
Copy-number alterations and chromosomal translocations are widespread in cancer and frequently causing oncogenic mutations that drive tumorigenesis and therapy resistance. Despite their preva...
The introduction of robot-assisted surgical technology into urological practice, has introduced new horizons for reducing the morbidity and enhancing the efficacy of surgery. Open radical cys...
This presentation will review the utility of multiparametric MRI (mpMRI) and genomic testing in the management of early stage prostate cancer and show when and if such tests should be used al...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Although about one in every seven men in the developed world will be diagnosed with prostate cancer in their lifetime, the mortality rate remains low with a 99% five-year survival rate for lo...
Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading cau...
Novel precision genetic technologies such as CRISPR/Cas9 genome editing technology offer novel avenues to a better understanding the mechanisms of diseases. Using CRISPR/Cas9 we are able to p...
Over the last decade, the policy and regulatory trajectory of genomic and reproductive technologies has been a checkered one. Approaches around the world range from constitutional and crimina...
CRISPR based gene editing has proven to be an incredibly powerful tool for studying functions of individual proteins, understanding the role of multi-gene pathways, and even knocking out prot...
First discovered as a genome-editing tool just seven years ago, CRISPR systems have already changed the face of basic research, allowing researchers to alter the DNA of hundreds of organisms...